Posts by John

The confirmatory trial failure of Zepzelca raises critical questions about the FDA’s Accelerated Approval pathway and the future of lung cancer treatments.

Adaptive DBS shows major potential in treating Parkinson's gait. We analyze why new FDA regulatory endpoints are essential for the future of the technology.

A new study confirms the efficacy of combining selinexor and ruxolitinib for myelofibrosis. Discover how this dual therapy improves patient outcomes.

New clinical trials reveal that preserving beta-cell function is the next frontier in diabetes care, potentially shifting treatment toward total remission.

Europe’s drug development sector faces a decline in R&D and market access. Discover why experts are demanding an overhaul to improve patient care.

Bulgaria is launching a strategic review to reform its heavily regulated pharma market, aiming to boost drug access and streamline medicinal approvals.

New research shows a breakthrough combination therapy significantly delays multiple myeloma progression and enhances survival outcomes for patients.

New research shows how model-informed dosing of carvedilol and nebivolol can safely improve cardiovascular treatment outcomes for patients with cirrhosis.

Discover how organoid technology is revolutionizing cancer research, bridging the gap between clinical trials and personalized, patient-centered therapy.

Neumora axes its lead depression drug after Phase 3 failure, while the FDA approves Colorado's state plan to import lower-cost prescription drugs from Canada.